You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行》中銀國際升先聲藥業(02096.HK)目標價至16.7元 上半年業績符合預期
阿思達克 08-25 15:29
中銀國際發表報告指,先聲藥業(02096.HK)上半年業績符合預期,收入按年增長15%至36億元人民幣,符合該行預期。調整後淨利潤為6.51億元人民幣,按年增長21.1%。 報告指,管理層維持2025年銷售額和經常性淨利潤按年增長15%以上的預期,並預計收入和淨利潤分別達到110億元人民幣和20億元人民幣。對於BD項目,其他潛在的授權資產包括先必新舌下片、FGFR2b ADC 和 CDH17 ADC。先聲藥業還致力於與全球合作夥伴合作開發其下一代ADC載荷平台,並於近期擴大了與Almirall的合作,共同開發多種用於自身免疫性疾病的雙特異性抗體產品。 業績發布後,該行微調了先聲藥業2025至2027年的營收預測,並將2025年及以後的潛在BD收入納入考量。預計BD收入將在2025至2027年貢獻分別總收入的2%、4%及7%。目標價由8.9港元升至16.7港元。維持「買入」評級。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account